Arch Therapeutics, Inc. (ARTH)

Market Cap	5.60M
Revenue (ttm)	115,331
Net Income (ttm)	-7.98M
Shares Out	4.74M
EPS (ttm)	-3.31
PE Ratio	n/a
Forward PE	0.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	618
Open	1.150
Previous Close	1.140
Day's Range	1.150 - 1.200
52-Week Range	0.390 - 18.000
Beta	3.56
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ARTH

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARTH

Financial Performance

In 2023, ARTH's revenue was $75,724, an increase of 383.80% compared to the previous year's $15,652. Losses were -$6.98 million, 63.3% more than in 2022.